Transverse Medical Inc. (TMI) is developing the POINT-GUARD™ Dynamic Cerebral Embolic Protection (CEP) medical device to address the devastating and costly problem of stroke during the large and growing number of heart valve procedures that occur annually around the world, such as Transcatheter Aortic Valve Replacement (TAVR).

Medical Devices

Transverse Medical

Eric Goslau

Michael Reardon

Daniel Estay

The Clinical Affairs Team at Transverse Medical is responsible for designing and overseeing clinical studies to evaluate the safety and efficacy of the POINT-GUARD™ Dynamic Cerebral Embolic Protection device. This team collaborates closely with regulatory agencies, medical professionals, and internal stakeholders to ensure compliance with clinical guidelines while supporting the advancement of innovative solutions to prevent stroke during heart valve procedures.

Clinical Affairs Team

About

Team members

Other teams at Transverse Medical

Leadership Team